X4 Pharmaceuticals, Inc.
XFOR
$0.21
-$0.0016-0.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.56% | 92.55% | 30.13% | 140.78% | 51.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.42% | 28.83% | 33.54% | 27.25% | -1.48% |
| Operating Income | -41.73% | -26.77% | -31.36% | -27.25% | 1.48% |
| Income Before Tax | -107.17% | -1,509.52% | 263.12% | -115.47% | 34.35% |
| Income Tax Expenses | 681.82% | -42.31% | 20.00% | 375.00% | 135.71% |
| Earnings from Continuing Operations | -108.16% | -1,492.02% | 263.04% | -115.51% | 34.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.16% | -1,492.02% | 263.04% | -115.51% | 34.27% |
| EBIT | -41.73% | -26.77% | -31.36% | -27.25% | 1.48% |
| EBITDA | -41.00% | -26.27% | -31.25% | -27.59% | 1.24% |
| EPS Basic | -103.95% | -1,461.54% | 237.25% | -57.23% | 66.69% |
| Normalized Basic EPS | -103.00% | -1,484.72% | 78.62% | -57.30% | 66.74% |
| EPS Diluted | -103.11% | -1,461.54% | 236.28% | -57.23% | 66.55% |
| Normalized Diluted EPS | -103.00% | -1,484.72% | 78.67% | -57.30% | 66.74% |
| Average Basic Shares Outstanding | 2.10% | 1.97% | 18.79% | 37.01% | 97.26% |
| Average Diluted Shares Outstanding | 2.10% | 1.97% | 19.00% | 37.01% | 97.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
